Cannara Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Cannara Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth57.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Jan 24
Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18
Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Jul 29
Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10
Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26
Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27
Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10
Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16
Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22
Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSXV:LOVE - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
11/30/2023669-26N/A
8/31/2023577-45N/A
5/31/2023515-13-1N/A
2/28/2023453-18-5N/A
11/30/2022403-19-7N/A
8/31/2022362-19-6N/A
5/31/2022301-41-2N/A
2/28/2022271-352N/A
11/30/2021221-322N/A
8/31/202117-2-33-2N/A
5/31/202111-7-9-6N/A
2/28/20215-11-13-10N/A
11/30/20203-13-14-9N/A
8/31/20203-12-19-9N/A
5/31/20203-12-22-8N/A
2/29/20202-12-30-9N/A
11/30/20192-13-34-9N/A
8/31/20192-12-31-7N/A
8/31/20181-4-30-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LOVE's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if LOVE's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if LOVE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LOVE's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if LOVE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LOVE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.